Is ROIV or MRNA more profitable?

Moderna has a net margin of -141.43% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Moderna -141.43% -28.30% -19.39%

Does the media prefer ROIV or MRNA?

In the previous week, Moderna had 27 more articles in the media than Roivant Sciences. MarketBeat recorded 39 mentions for Moderna and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.64 beat Moderna's score of 0.25 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 7 Very Positive mention(s) 9 Positive mention(s) 15 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to REGN or ROIV?

In the previous week, Regeneron Pharmaceuticals had 13 more articles in the media than Roivant Sciences. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.64 beat Regeneron Pharmaceuticals' score of 0.39 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 5 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Roivant Sciences 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ROIV or NTRA?

Natera has higher revenue and earnings than Roivant Sciences. Natera is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 2,991.59 -$299.77M -$0.53 N/A Natera $2.31B 24.43 -$208.16M -$1.36 N/A

Is ROIV or NTRA more profitable?

Natera has a net margin of -7.11% compared to Roivant Sciences' net margin of -3,534.96%. Natera's return on equity of -11.38% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Natera -7.11% -11.38% -7.87%

Does the media refer more to ROIV or NTRA?

In the previous week, Natera had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 21 mentions for Natera and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.64 beat Natera's score of 0.13 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ARGX or ROIV?

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $5.23B 9.80 $1.29B $26.04 31.44 Roivant Sciences $8.26M 2,991.59 -$299.77M -$0.53 N/A

Is ARGX or ROIV more profitable?

argenex has a net margin of 32.19% compared to Roivant Sciences' net margin of -3,534.96%. argenex's return on equity of 43.59% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media favor ARGX or ROIV?

In the previous week, argenex had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 19 mentions for argenex and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.64 beat argenex's score of 0.21 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 5 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ROIV or RVMD?

In the previous week, Roivant Sciences had 3 more articles in the media than Revolution Medicines. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for Revolution Medicines. Roivant Sciences' average media sentiment score of 0.64 beat Revolution Medicines' score of 0.14 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Roivant Sciences (ROIV) Competitors

$35.12 +0.91 (+2.65%)

As of 01:05 PM Eastern

Compare

ROIV vs. MRNA, REGN, NTRA, ARGX, and RVMD

Should you buy Roivant Sciences stock or one of its competitors? Roivant Sciences's main competitors and comparable companies include Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Natera (NTRA), argenex (ARGX), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Roivant Sciences compare to Moderna?

Roivant Sciences (NASDAQ:ROIV) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Moderna had 27 more articles in the media than Roivant Sciences. MarketBeat recorded 39 mentions for Moderna and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.64 beat Moderna's score of 0.25 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	7 Very Positive mention(s)	9 Positive mention(s)	15 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Roivant Sciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Moderna has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Roivant Sciences presently has a consensus price target of $45.64, indicating a potential upside of 33.40%. Moderna has a consensus price target of $78.17, indicating a potential downside of 60.32%. Given Roivant Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Roivant Sciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Roivant Sciences has higher earnings, but lower revenue than Moderna. Roivant Sciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A
Moderna	$1.94B	40.46	-$2.82B	-$7.99	N/A

Moderna has a net margin of -141.43% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Moderna	-141.43%	-28.30%	-19.39%

Summary

Roivant Sciences beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals currently has a consensus price target of $817.92, suggesting a potential upside of 10.59%. Roivant Sciences has a consensus price target of $45.64, suggesting a potential upside of 33.40%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.69
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Regeneron Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.31	$4.50B	$40.46	18.28
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Roivant Sciences' net margin of -3,534.96%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, Regeneron Pharmaceuticals had 13 more articles in the media than Roivant Sciences. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.64 beat Regeneron Pharmaceuticals' score of 0.39 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	5 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats Roivant Sciences on 10 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to Natera?

Roivant Sciences (NASDAQ:ROIV) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Roivant Sciences presently has a consensus target price of $45.64, indicating a potential upside of 33.40%. Natera has a consensus target price of $353.45, indicating a potential downside of 9.55%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Roivant Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Natera has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Natera has higher revenue and earnings than Roivant Sciences. Natera is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A
Natera	$2.31B	24.43	-$208.16M	-$1.36	N/A

Natera has a net margin of -7.11% compared to Roivant Sciences' net margin of -3,534.96%. Natera's return on equity of -11.38% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Natera	-7.11%	-11.38%	-7.87%

In the previous week, Natera had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 21 mentions for Natera and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.64 beat Natera's score of 0.13 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Natera beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to argenex?

argenex (NASDAQ:ARGX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

argenex presently has a consensus price target of $1,158.61, suggesting a potential upside of 41.53%. Roivant Sciences has a consensus price target of $45.64, suggesting a potential upside of 33.40%. Given argenex's stronger consensus rating and higher probable upside, research analysts plainly believe argenex is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

argenex has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

60.3% of argenex shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

argenex has a net margin of 32.19% compared to Roivant Sciences' net margin of -3,534.96%. argenex's return on equity of 43.59% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, argenex had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 19 mentions for argenex and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.64 beat argenex's score of 0.21 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	5 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$5.23B	9.80	$1.29B	$26.04	31.44
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A

Summary

argenex beats Roivant Sciences on 12 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Revolution Medicines?

Roivant Sciences (NASDAQ:ROIV) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

In the previous week, Roivant Sciences had 3 more articles in the media than Revolution Medicines. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for Revolution Medicines. Roivant Sciences' average media sentiment score of 0.64 beat Revolution Medicines' score of 0.14 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revolution Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Revolution Medicines	N/A	-88.20%	-57.85%

Roivant Sciences currently has a consensus price target of $45.64, suggesting a potential upside of 33.40%. Revolution Medicines has a consensus price target of $234.76, suggesting a potential upside of 24.79%. Given Roivant Sciences' higher probable upside, equities analysts plainly believe Roivant Sciences is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Roivant Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Roivant Sciences has higher earnings, but lower revenue than Revolution Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A
Revolution Medicines	$11.58M	3,482.01	-$1.13B	-$8.82	N/A

Summary

Roivant Sciences and Revolution Medicines tied by winning 8 of the 16 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ROIV vs. The Competition

Export

Metric	Roivant Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.07B	$3.88B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-65.48	13.29	274.63	26.11
Price / Sales	3,040.56	1,195.64	586.31	81.01
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	4.73	16.46	10.93	6.31
Net Income	-$299.77M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-2.66%	-1.44%	-0.94%	-1.34%
1 Month Performance	-16.84%	-9.73%	-5.45%	-4.31%
1 Year Performance	115.69%	10.19%	4.43%	-0.35%

Roivant Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ROIV Roivant Sciences	3.2524 of 5 stars	$35.12 +2.6%	$45.64 +30.0%	+113.4%	$25.35B	$8.26M	N/A	721
MRNA Moderna	1.9474 of 5 stars	$203.21 +6.9%	$77.83 -61.7%	+605.6%	$75.86B	$2.21B	N/A	4,700	Trending News Analyst Forecast
REGN Regeneron Pharmaceuticals	4.2475 of 5 stars	$726.47 -1.2%	$809.50 +11.4%	+31.2%	$75.69B	$14.34B	17.96	15,410	Analyst Forecast
NTRA Natera	2.2082 of 5 stars	$425.64 +3.7%	$341.55 -19.8%	+127.1%	$59.15B	$2.31B	N/A	6,140	Analyst Forecast
ARGX argenex	4.7047 of 5 stars	$912.87 -0.7%	$1,158.61 +26.9%	+2.5%	$57.51B	$5.23B	35.06	1,863	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ROIV) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Competitors

ROIV vs. MRNA, REGN, NTRA, ARGX, and RVMD

How does Roivant Sciences compare to Moderna?

Summary

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Summary

How does Roivant Sciences compare to Natera?

Summary

How does Roivant Sciences compare to argenex?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Competitors

ROIV vs. MRNA, REGN, NTRA, ARGX, and RVMD

How does Roivant Sciences compare to Moderna?

Does the media prefer ROIV or MRNA?

Do institutionals and insiders have more ownership in ROIV or MRNA?

Which has more risk and volatility, ROIV or MRNA?

Do analysts prefer ROIV or MRNA?

Which has higher valuation and earnings, ROIV or MRNA?

Is ROIV or MRNA more profitable?

Summary

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Do insiders & institutionals hold more shares of REGN or ROIV?

Do analysts prefer REGN or ROIV?

Which has higher earnings and valuation, REGN or ROIV?

Is REGN or ROIV more profitable?

Does the media refer more to REGN or ROIV?

Which has more risk & volatility, REGN or ROIV?

Summary

How does Roivant Sciences compare to Natera?

Do analysts prefer ROIV or NTRA?

Which has more risk and volatility, ROIV or NTRA?

Do insiders and institutionals believe in ROIV or NTRA?

Which has stronger earnings and valuation, ROIV or NTRA?

Is ROIV or NTRA more profitable?

Does the media refer more to ROIV or NTRA?

Summary

How does Roivant Sciences compare to argenex?

Do analysts prefer ARGX or ROIV?

Which has more risk & volatility, ARGX or ROIV?

Do insiders & institutionals believe in ARGX or ROIV?

Is ARGX or ROIV more profitable?

Does the media favor ARGX or ROIV?

Which has preferable valuation and earnings, ARGX or ROIV?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Does the media refer more to ROIV or RVMD?

Is ROIV or RVMD more profitable?

Do analysts recommend ROIV or RVMD?

Do insiders and institutionals have more ownership in ROIV or RVMD?

Which has more risk & volatility, ROIV or RVMD?

Which has higher valuation & earnings, ROIV or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools